The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $9.75 for the day, up 2.52% from the previous closing price of $9.51. In other words, the price has increased by $+0.24 from its previous closing price. On the day, 3617056 shares were traded.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 6.34. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 668.86M and an Enterprise Value of 486.15M. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.22 while its Price-to-Book (P/B) ratio in mrq is 2.40. Its current Enterprise Value per Revenue stands at 23.42 whereas that against EBITDA is -3.80.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $9.80, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 6.21, while the 200-Day Moving Average is calculated to be 3.51.
Shares Statistics:
CCCC traded an average of 15.49M shares per day over the past three months and 3.57M shares per day over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 53.47M. Insiders hold about 22.06% of the company’s shares, while institutions hold 65.89% stake in the company. Shares short for CCCC as of Jan 31, 2024 were 3.35M with a Short Ratio of 0.22, compared to 4.54M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.81% and a Short% of Float of 11.55%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.37 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.6, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.39 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.33 and -$2.52 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$2.15, with 8 analysts recommending between -$1.54 and -$3.15.
